Impact BioMedical, Inc. (IBO)vsNovartis AG ADR (NVS)
IBO
Impact BioMedical, Inc.
$0.66
-2.59%
HEALTHCARE · Cap: $71.16M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 176806147% more annual revenue ($56.58B vs $32,000). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
IBO
Avoid15
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IBO.
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : IBO
The strongest argument for IBO centers on Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : IBO
The primary concerns for IBO are Revenue Growth, EPS Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
IBO profiles as a value stock while NVS is a declining play — different risk/reward profiles.
IBO is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 15/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Impact BioMedical, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Impact BioMedical, Inc. is a forward-thinking biotechnology firm dedicated to the development of pioneering therapeutics and technologies that tackle pressing healthcare issues. The company employs cutting-edge research and development methodologies to enhance patient health outcomes and elevate quality of life. With a strong intellectual property portfolio and a focus on scientific excellence, Impact BioMedical is strategically positioned for significant growth in the dynamic healthcare landscape. Its diverse product pipeline and strategic partnerships present promising opportunities for institutional investors seeking to invest in the transformative advancements of the biopharmaceutical sector.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?